...
机译:日本t(8; 21)急性髓性白血病患者微弱残留病的临床意义
Department of Hematology and Oncology Toyohashi Municipal Hospital Toyohashi Japan;
Department of Hematology Yamanashi Prefectural Central Hospital Kofu Japan;
Department of Hematology Okazaki City Hospital Okazaki Japan;
Department of Hematology/Oncology Clinical Research Center National Hospital Organization Nagoya Medical Center Nagoya Japan;
Department of Hematology Komaki City Hospital Komaki Japan;
Department of Infectious Diseases Nagoya University School of Medicine Nagoya Japan;
Department of Hematology Yokkaichi Municipal Hospital Yokkaichi Japan;
Department of Hematology and Oncology Toyohashi Municipal Hospital Toyohashi Japan;
Department of Hematology Meitetsu Hospital Nagoya Japan;
Department of Internal Medicine Fujita Health University School of Medicine Toyoake Japan;
Department of Hematology and Oncology Nagoya University Graduate School of Medicine 65 Tsurumai-cho Showa-ku Nagoya Aichi 466-8550 Japan;
Department of Hematology and Oncology Nagoya University Graduate School of Medicine 65 Tsurumai-cho Showa-ku Nagoya Aichi 466-8550 Japan;
Department of HSCT Data Management Nagoya University School of Medicine Nagoya Japan;
Department of Hematology and Oncology Toyohashi Municipal Hospital Toyohashi Japan;
Acute myeloid leukemia; t(8; 21); RUNX/MTG8; Minimal residual disease; Prognosis;
机译:日本t(8; 21)急性骨髓性白血病患者微弱残留病的临床意义。
机译:DCOG ANLL97 | [sol] | MRC AML12方案治疗的小儿急性髓细胞性白血病患者流式细胞术最小残留疾病检测的临床意义
机译:干扰素对异基因造血干细胞移植后t(8; 21)急性髓细胞性白血病患者的最小残留疾病有效:前瞻性登记研究结果
机译:带有注意力网络的BLSTM,可使用综合的临床参数预测急性髓性白血病患者的预后
机译:根据2017年日本成人白血病研究组(JALSG)AML201研究治疗的成人急性髓性白血病患者的遗传学预测,根据2017 ELN风险分层进行预后分析
机译:干扰素-α对异基因造血干细胞移植后t(8; 21)急性髓细胞性白血病患者的最小残留疾病有效:前瞻性登记研究结果
机译:Interferon-α是治疗T(8; 21)急性髓样白血病患者的最小残留疾病的有效性:前瞻性注册表研究的结果